Literature DB >> 18696715

Prostate-specific antigen screening among young men in the United States.

Charles D Scales1, Jodi Antonelli, Lesley H Curtis, Kevin A Schulman, Judd W Moul.   

Abstract

BACKGROUND: Disagreement exists on the use of prostate-specific antigen (PSA) tests for cancer-risk stratification in young men in the United States. Little is known about the use of PSA testing in these men. To understand policy implications of risk stratification, the authors sought to characterize PSA use among young men.
METHODS: The authors used the 2002 Behavioral Risk Factor Surveillance System to study prostate-cancer screening in a representative sample of men aged 40 years and older (n = 58,511). The primary outcome was self-report of a PSA test in the previous year.
RESULTS: Among men aged 40 to 49 years, 22.5% (95% confidence interval [CI], 21.5-23.5) reported having had a PSA test in the previous year, compared with 53.7% (95% CI, 52.8-54.7; P < .001) of men aged >or=50 years. When sociodemographic characteristics were statistically controlled, young, black, non-Hispanic men were more likely than young, white, non-Hispanic men to report having had a PSA test in the previous year (odds ratio [OR], 2.42; 95% CI, 1.95-3.01; P < .001). In young men, annual household income >or=USD 35,000 (OR, 1.50; 95% CI, 1.26-1.78; P < .001) and an ongoing relationship with a physician (OR, 2.52; 95% CI, 2.06-3.07; P < .001) were associated with PSA testing.
CONCLUSIONS: One-fifth of young men reported having had a PSA test within the previous year. Young, black, non-Hispanic men are more likely than young, white, non-Hispanic men to report having had a PSA test, although screening in this high-risk group remains suboptimal. (c) 2008 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18696715     DOI: 10.1002/cncr.23667

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Experiences of Uncertainty in Men With an Elevated PSA.

Authors:  Caitlin Biddle; Alicia Brasel; Willie Underwood; Heather Orom
Journal:  Am J Mens Health       Date:  2016-06-23

Review 2.  Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale.

Authors:  Tiffany A Wallace; Damali N Martin; Stefan Ambs
Journal:  Carcinogenesis       Date:  2011-04-03       Impact factor: 4.944

Review 3.  Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer.

Authors:  Ganna Chornokur; Kyle Dalton; Meghan E Borysova; Nagi B Kumar
Journal:  Prostate       Date:  2010-12-28       Impact factor: 4.104

4.  Racial/ethnic differences in predictors of PSA screening in a tri-ethnic population.

Authors:  G M Monawar Hosain; Maureen Sanderson; Xianglin L Du; Wenyaw Chan; Sara S Strom
Journal:  Cent Eur J Public Health       Date:  2011-03       Impact factor: 1.163

5.  Use of the prostate-specific antigen test among men aged 75 years or older in the United States: 2006 Behavioral Risk Factor Surveillance System.

Authors:  Jun Li; Guixiang Zhao; Lori A Pollack; Judith Lee Smith; Djenaba A Joseph
Journal:  Prev Chronic Dis       Date:  2010-06-15       Impact factor: 2.830

6.  Contemporary risk profile of prostate cancer in the United States.

Authors:  Yu-Hsuan Shao; Kitaw Demissie; Weichung Shih; Amit R Mehta; Mark N Stein; Calpurnyia B Roberts; Robert S Dipaola; Grace L Lu-Yao
Journal:  J Natl Cancer Inst       Date:  2009-08-27       Impact factor: 13.506

7.  Predictors of repeated PSA testing among black and white men from the Maryland Cancer Survey, 2006.

Authors:  Yue Zhu; John D Sorkin; Diane Dwyer; Carmela Groves; Eileen K Steinberger
Journal:  Prev Chronic Dis       Date:  2011-08-15       Impact factor: 2.830

8.  Prostate-specific antigen testing in inner London general practices: are those at higher risk most likely to get tested?

Authors:  Paul Nderitu; Mieke Van Hemelrijck; Mark Ashworth; Rohini Mathur; Sally Hull; Alexandra Dudek; Simon Chowdhury
Journal:  BMJ Open       Date:  2016-07-12       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.